<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02650479</url>
  </required_header>
  <id_info>
    <org_study_id>ITCA-650-CLP-114</org_study_id>
    <nct_id>NCT02650479</nct_id>
  </id_info>
  <brief_title>Study of the Effects of Intravenous Exenatide on Cardiac Repolarization</brief_title>
  <official_title>Two-Part, Randomized, Placebo and Active-Controlled, Double-Blind, Thorough QT Study Evaluating the Effects of Intravenous Exenatide on Cardiac Repolarization in Healthy Male and Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intarcia Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intarcia Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Two-Part, Randomized, Placebo and Active-Controlled, Double-Blind, Thorough QT Study&#xD;
      Evaluating the Effects of Intravenous Exenatide on Cardiac Repolarization in Healthy Male and&#xD;
      Female Volunteers&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This single-center Phase I study will consist of 2 parts, a Pilot Part and a Core Part.&#xD;
&#xD;
      The Pilot Part of the study will be an open-label, non-randomized, single-treatment design in&#xD;
      10 healthy male and female subjects to determine if an infusion regimen of a 6-h continuous&#xD;
      IV infusion of exenatide will lead to a mean plasma steady state concentration of 500 pg/mL.&#xD;
&#xD;
      The Core part of the study will be a double-blind (except for the use of open label active&#xD;
      control moxifloxacin), randomized, placebo-controlled,3 period, 6-sequence, cross-over design&#xD;
      in 72 healthy male and female subjects to evaluate whether exenatide at therapeutic and&#xD;
      supra-therapeutic concentrations has a pharmacological effect on cardiac repolarization&#xD;
      (threshold value &gt;10 msec).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pilot Study: Establishment of mean plasma steady state concentration of 500 pg/mL</measure>
    <time_frame>35 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Core Study: Changes to QTc interval changes (threshold &gt; 10 msec) measurements</measure>
    <time_frame>56 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pilot Study: Adverse events as assessed by subjective subject reporting, laboratory testing, ECG, physical examinations, and vital signs</measure>
    <time_frame>35 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Core Study: Measurement of exenatide plasma concentrations and relationship to changes in QTc interval measurements</measure>
    <time_frame>56 days</time_frame>
    <description>Relationship between plasma concentrations of exenatide and QTc interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Core Study: Changes in PR, RR, QRS, QT, T- and U- wave morphology</measure>
    <time_frame>56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Core Study: Measurement of QTc interval changes moxifloxacin as active control</measure>
    <time_frame>56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Core Study: Adverse events as assessed by subjective subject reporting, laboratory testing, ECG, physical examinations, and vital signs</measure>
    <time_frame>56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pilot Study: Maximum concentration (CMax) of exenatide</measure>
    <time_frame>35 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pilot Study: Time to maximum concentration (TMax) of exenatide</measure>
    <time_frame>35 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pilot Study: Area under the curve (AUC) of exenatide</measure>
    <time_frame>35 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pilot Study: Steady state concentration (Css) of exenatide</measure>
    <time_frame>35 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pilot Study: Half life (T1/2) of exenatide</measure>
    <time_frame>35 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Core Study: Half life (T1/2) of exenatide</measure>
    <time_frame>56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Core Study: Steady state concentration (Css) of exenatide</measure>
    <time_frame>56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Core Study: Area under the curve (AUC) of exenatide</measure>
    <time_frame>56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Core Study: Maximum concentration (CMax)</measure>
    <time_frame>56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Core Study: Time to maximum concentration (TMax) of exenatide</measure>
    <time_frame>56 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Healthy Adult Male and Female Volunteers</condition>
  <arm_group>
    <arm_group_label>IV exenatide - pilot study</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>IV Exenatide Infusion 0.1250 mcg/kg/hour for 0.5 hours followed by 0.0625 mcg/kg/hour for 5.5 hours, preceded by IV Palonosetron 0.25 mg for nausea/vomiting prophylaxis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group A - core study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV Exenatide Infusion 0.1250 mcg/kg/hour for 0.5 hours followed by 0.0625 mcg/kg/hour for 5.5 hours, preceded by IV Palonosetron 0.25 mg for nausea/vomiting prophylaxis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group B - core study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV infusion of placebo over 6 hours, preceded by IV Palonosetron 0.25 mg for nausea/vomiting prophylaxis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group C - core study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV infusion of placebo over 6 hours and a single oral dose of 400 mg moxifloxacin within 1 min of start of infusion, preceded by IV Palonosetron 0.25 mg for nausea/vomiting prophylaxis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide</intervention_name>
    <description>6 hour IV infusion (double infusion of 0.1250 mcg/kg/hour for 30 min followed by infusion rate (1X) of 0.0625 mcg/kg/hour for 5.5 hours).</description>
    <arm_group_label>IV exenatide - pilot study</arm_group_label>
    <arm_group_label>Treatment Group A - core study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>6 hour IV infusion.</description>
    <arm_group_label>Treatment Group B - core study</arm_group_label>
    <arm_group_label>Treatment Group C - core study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>400 mg oral dose moxifloxacin within 1 min of start of infusion of exenatide</description>
    <arm_group_label>Treatment Group C - core study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palonosetron</intervention_name>
    <description>0.25 mg administered IV within 30 minutes prior to initiating the infusion of exenatide</description>
    <arm_group_label>IV exenatide - pilot study</arm_group_label>
    <arm_group_label>Treatment Group A - core study</arm_group_label>
    <arm_group_label>Treatment Group B - core study</arm_group_label>
    <arm_group_label>Treatment Group C - core study</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index (BMI) between 19 to 35 kg/m2 inclusive.&#xD;
&#xD;
          -  Women of child bearing potential - use of an additional adequate method of&#xD;
             contraception during the study and until 1 additional menstrual cycle following the&#xD;
             end-of-study (EOS) visit. Adequate methods of contraception for women of child bearing&#xD;
             potential (WOCBP) include: mechanical products (ie, intrauterine device [IUD]-copper&#xD;
             IUD); or barrier methods (eg, diaphragm, condoms, cervical cap) with spermacide.&#xD;
&#xD;
          -  Aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase&#xD;
             (AP), and bilirubin within normal range at Screening.&#xD;
&#xD;
          -  Fasting triglycerides within the normal range at Screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of type 1 or type 2 diabetes, or history of hypoglycemia.&#xD;
&#xD;
          -  History or evidence of myocardial infarction, congestive heart failure, syncope not&#xD;
             related to heart arrhythmia, coronary revascularization (coronary artery bypass&#xD;
             grafting or percutaneous coronary intervention), unstable angina, or cerebrovascular&#xD;
             accident or stroke or TIA.&#xD;
&#xD;
          -  History of atrial fibrillation, flutter, or non-sustained or sustained VT.&#xD;
&#xD;
          -  Personal or family history of sudden death or long QT syndrome.&#xD;
&#xD;
          -  History of uncontrolled hypertension.&#xD;
&#xD;
          -  History or evidence of acute or chronic pancreatitis.&#xD;
&#xD;
          -  History of liver disease.&#xD;
&#xD;
          -  Abnormal renal function.&#xD;
&#xD;
          -  History of medullary thyroid cancer or a personal or family history of multiple&#xD;
             endocrine neoplasia type 2.&#xD;
&#xD;
          -  Thyroid-stimulating hormone (TSH) outside of normal limits at Screening .&#xD;
&#xD;
          -  Weight loss surgery.&#xD;
&#xD;
          -  History of malignancy (not including basal or squamous cell carcinoma of the skin with&#xD;
             past 5 years). (Subjects who have been disease free for greater than 5 years may be&#xD;
             included.)&#xD;
&#xD;
          -  History of active alcohol within 1 year prior to Screening.&#xD;
&#xD;
          -  History of drug abuse within 5 years prior to Screening or a positive prestudy drug&#xD;
             screen.&#xD;
&#xD;
          -  Weekly consumption of more than 14 alcoholic beverages for females and more than 21&#xD;
             alcoholic beverages for males.&#xD;
&#xD;
          -  Smoke more than 10 cigarettes per day.&#xD;
&#xD;
          -  Excessive in xanthine consumption (more than 5 cups of coffee or equivalent per day).&#xD;
&#xD;
          -  History of hypersensitivity to any of the medications used in this study.&#xD;
&#xD;
          -  Women that are pregnant, lactating, or planning to become pregnant.&#xD;
&#xD;
          -  History of or positive results on screening tests for hepatitis B and/or hepatitis C&#xD;
             and/or human immunodeficiency virus (HIV).&#xD;
&#xD;
          -  History or evidence of immunocompromised status.&#xD;
&#xD;
          -  Prior or current treatment with any GLP-1 receptor agonist (eg, Bydureon™, Byetta®,&#xD;
             Victoza®, Tanzeum® or exogenous native GLP-1) or prior participation in an ITCA 650&#xD;
             clinical trial.&#xD;
&#xD;
          -  Any gastrointestinal complaints within 7 days prior to first dosing.&#xD;
&#xD;
          -  Use of medications within 14 days of first dose other than hormone replacement therapy&#xD;
             and oral contraceptives.&#xD;
&#xD;
          -  Chronic (8 consecutive days or greater) treatment with systemic corticosteroids.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>PRA-Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>January 1, 2016</study_first_submitted>
  <study_first_submitted_qc>January 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2016</study_first_posted>
  <last_update_submitted>January 26, 2017</last_update_submitted>
  <last_update_submitted_qc>January 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Palonosetron</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

